In one paragraphArticle in ChemMedChem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors at 2 institutions in 1 country.
Suhas S BhosaleDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, KY, 40536, USA.ORCID 0000-0002-9434-7093 Abhisek MandalDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, KY, 40536, USA.
Caixia HouDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, KY, 40536, USA.
J Robert McCorkleMarkey Cancer Center, University of Kentucky, 760 S. Rose Street, Lexington, KY, 40536, USA.
David SchweerDivision of Gynecologic Oncology, College of Medicine, 760 S. Rose Street, Lexington, KY, 40536, USA.
Kristen S HillMarkey Cancer Center, University of Kentucky, 760 S. Rose Street, Lexington, KY, 40536, USA.
Vivekanandan SubramanianUniversity of Kentucky PharmNMR Center, College of Pharmacy, University of Kentucky, Lexington, KY, 40536-0596, USA.ORCID 0000-0003-4338-6153 Jill M KolesarMarkey Cancer Center, University of Kentucky, 760 S. Rose Street, Lexington, KY, 40536, USA.ORCID 0000-0003-1802-6439 Oleg V TsodikovDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, KY, 40536, USA.ORCID 0000-0001-7094-4216 Jürgen RohrDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, KY, 40536, USA.ORCID 0000-0001-6447-5951 University of Kentucky · USGynecologic Oncology Group · US
Funding
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3MMechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcomaR01CA243529 · NCI · UNIVERSITY OF KENTUCKY · PI LEGGAS, MARKOS, ROHR, JURGEN T · 2020 to 2024
$3.0MBruker AVANCE NEO 600 MHz High-Performance Digital NMR SpectrometerS10OD028690 · OD · UNIVERSITY OF KENTUCKY · PI GARNEAU-TSODIKOVA, SYLVIE · 2020 to 2020
$1.4MNCI NIH HHS P30 CA177558NCI NIH HHS P30CA177558NCI NIH HHS R01 CA243529NIH HHS S10 OD028690
6 · The paper itselfAbstract
DNA coordinating platinum (Pt) containing compounds cisplatin and carboplatin have been used for the treatment of ovarian cancer therapy for four decades. However, recurrent Pt-resistant cancers are a major cause of mortality. To combat Pt-resistant ovarian cancers, we designed and synthesized a conjugate of an anticancer drug mithramycin with a reactive Pt(II) bearing moiety, which we termed mithplatin. The conjugates displayed both the Mg
Indexed as
Antineoplastic AgentsOvarian NeoplasmsCell Line, TumorCisplatinDNADrug Resistance, NeoplasmFemaleHumansPlicamycinAntineoplastic AgentsCisplatinDNAPlicamycinDNA cross linkingMithramycinOvarian cancerPlatinum complexesPlatinum resistance
Identifiers
PMID36342449
PMCPMC9899322
OpenAlexW4308370960
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390